Patient characteristics
| Characteristic . | TP53WT (n = 300) . | TP53MT single-hit (n = 19) . | TP53MT multihit (n = 30) . | P . |
|---|---|---|---|---|
| Age, y, median (range) | 58 (22-75) | 52 (44-74) | 58 (24-75) | .62 |
| Female sex, n (%) | 99 (40) | 8 (47) | 14 (48) | .58 |
| Diagnosis, n (%) | .23 | |||
| Primary myelofibrosis | 214 (71) | 14 (74) | 17 (57) | |
| Secondary myelofibrosis | 86 (29) | 5 (26) | 13 (43) | |
| Circulating blasts, %, median (range) | 1 (0-19) | 1 (0-12) | 1 (0-19) | .85 |
| Platelets, ×109/L, median (range) | 144 (4-2437) | 160 (20-975) | 90 (5-623) | .02 |
| WBC, ×109/L, median (range) | 7.0 (0.1-107.1) | 9.8 (0.2-43.0) | 6.2 (0.2-168.8) | .44 |
| Hb, g/dL, median (range) | 9.4 (5.6-17.9) | 9.3 (7.3-13.6) | 8.4 (6.8-11.9) | .03 |
| KPS <90%, n (%) | 115 (39) | 10 (53) | 18 (60) | .04 |
| Constitutional symptoms, n (%) | 168 (56) | 11 (42) | 14 (47) | .33 |
| Driver mutation, n (%) | .16 | |||
| CALR | 61 (20) | 8 (42) | 5 (17) | |
| JAK2 | 175 (58) | 7 (37) | 17 (57) | |
| MPL | 16 (5) | 1 (5) | 0 (0) | |
| Triple negative | 48 (16) | 3 (16) | 8 (27) | |
| High molecular risk, n (%) | 104 (44) | 6 (35) | 10 (35) | .54 |
| Cytogenetic risk, n (%) | .004 | |||
| Favorable | 220 (73) | 13 (68) | 15 (50) | |
| Unfavorable | 60 (20) | 4 (21) | 15 (50) | |
| Very high risk | 20 (7) | 2 (11) | 0 (0) | |
| Complex karyotype, n (%) | 22 (7) | 0 (0) | 14 (47) | <.001 |
| Ruxolitinib pre-HSCT, n (%) | 124 (42) | 6 (32) | 6 (20) | .05 |
| Donor relation, n (%) | .15 | |||
| MRD | 68 (23) | 9 (48) | 6 (20) | |
| MUD | 161 (54) | 7 (37) | 13 (43) | |
| MMRD | 9 (3) | 0 (0) | 2 (7) | |
| MMUD | 62 (21) | 3 (16) | 9 (30) | |
| Conditioning intensity, n (%) | <.001 | |||
| Reduced | 261 (87) | 9 (47) | 15 (50) | |
| Myeloablative | 39 (13) | 10 (53) | 15 (50) | |
| ATG for GVHD prophylaxis, n (%) | 206 (69) | 12 (63) | 20 (67) | .87 |
| Time to HSCT in months, median (range) | 26 (0.5-567) | 33 (4.6-266.3) | 14.2 (2.0-356.6) | .58 |
| Characteristic . | TP53WT (n = 300) . | TP53MT single-hit (n = 19) . | TP53MT multihit (n = 30) . | P . |
|---|---|---|---|---|
| Age, y, median (range) | 58 (22-75) | 52 (44-74) | 58 (24-75) | .62 |
| Female sex, n (%) | 99 (40) | 8 (47) | 14 (48) | .58 |
| Diagnosis, n (%) | .23 | |||
| Primary myelofibrosis | 214 (71) | 14 (74) | 17 (57) | |
| Secondary myelofibrosis | 86 (29) | 5 (26) | 13 (43) | |
| Circulating blasts, %, median (range) | 1 (0-19) | 1 (0-12) | 1 (0-19) | .85 |
| Platelets, ×109/L, median (range) | 144 (4-2437) | 160 (20-975) | 90 (5-623) | .02 |
| WBC, ×109/L, median (range) | 7.0 (0.1-107.1) | 9.8 (0.2-43.0) | 6.2 (0.2-168.8) | .44 |
| Hb, g/dL, median (range) | 9.4 (5.6-17.9) | 9.3 (7.3-13.6) | 8.4 (6.8-11.9) | .03 |
| KPS <90%, n (%) | 115 (39) | 10 (53) | 18 (60) | .04 |
| Constitutional symptoms, n (%) | 168 (56) | 11 (42) | 14 (47) | .33 |
| Driver mutation, n (%) | .16 | |||
| CALR | 61 (20) | 8 (42) | 5 (17) | |
| JAK2 | 175 (58) | 7 (37) | 17 (57) | |
| MPL | 16 (5) | 1 (5) | 0 (0) | |
| Triple negative | 48 (16) | 3 (16) | 8 (27) | |
| High molecular risk, n (%) | 104 (44) | 6 (35) | 10 (35) | .54 |
| Cytogenetic risk, n (%) | .004 | |||
| Favorable | 220 (73) | 13 (68) | 15 (50) | |
| Unfavorable | 60 (20) | 4 (21) | 15 (50) | |
| Very high risk | 20 (7) | 2 (11) | 0 (0) | |
| Complex karyotype, n (%) | 22 (7) | 0 (0) | 14 (47) | <.001 |
| Ruxolitinib pre-HSCT, n (%) | 124 (42) | 6 (32) | 6 (20) | .05 |
| Donor relation, n (%) | .15 | |||
| MRD | 68 (23) | 9 (48) | 6 (20) | |
| MUD | 161 (54) | 7 (37) | 13 (43) | |
| MMRD | 9 (3) | 0 (0) | 2 (7) | |
| MMUD | 62 (21) | 3 (16) | 9 (30) | |
| Conditioning intensity, n (%) | <.001 | |||
| Reduced | 261 (87) | 9 (47) | 15 (50) | |
| Myeloablative | 39 (13) | 10 (53) | 15 (50) | |
| ATG for GVHD prophylaxis, n (%) | 206 (69) | 12 (63) | 20 (67) | .87 |
| Time to HSCT in months, median (range) | 26 (0.5-567) | 33 (4.6-266.3) | 14.2 (2.0-356.6) | .58 |
High molecular risk was defined as the presence of mutations in ASXL1, SRSF2, EZH2, or IDH1/2.17
ATG, antithymocyte globulin; GVHD, graft-versus-host disease; Hb, hemoglobin; KPS, Karnofsky Performance Status; MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; WBC, white blood cell.
Bold font indicates statistical significance.